Mother's delight as gene therapy offers hope to three-year-old
Three-year-old Gunreet Kaur has a rare inherited condition that affects children's physical, mental and behavioural development.
Children with aromatic l-amino acid decarboxylase (AADC) deficiency find it difficult to control their head, blood pressure and heart rate.
Sandeep Kaur said Gunreet has made 'great progress' since her treatment (Handout/PA)
But after receiving the new gene therapy, called Upstaza, Gunreet has made progress that her mother thought would never be possible, such as new movements and vocalising.
It is hoped that she will make further strides as she ages.
Gunreet, from Hayes in west London, was nine months old when she was diagnosed with the condition.
She received the treatment in February 2024 at the world-renowned Great Ormond Street children's hospital (GOSH), which is the only hospital in the UK offering the treatment to children.
Sandeep Kaur said Gunreet has made 'great progress' since her treatment.
'When Gunreet was about seven months old I noticed she wasn't reaching her milestones at the same age that her older brother did,' she said.
'She couldn't hold her own head up or reach out for items. She cried a lot and always wanted to be held.
'Since having the gene therapy, Gunreet has made great progress.
'She cries less, smiles more, and can reach for objects.
'She can hold her head up and is trying to sit up, she's recently learned how to roll from her stomach to her back which is fantastic to see.
'It means a lot to me that Gunreet was able to have this gene therapy – her general health has improved, she has more co-ordination, she can bring her palms together and is able to move her hand to her mouth.'
Sandeep Kaur said Gunreet's health and coordination has improved post-treatment (Handout/PA)
AADC deficiency is caused by a mutation in the gene that produces the AADC enzyme, this enzyme is needed to produce a neurotransmitter called dopamine which is important in controlling movement.
People with AADC deficiency do not have a working version of the enzyme, which means that they have little or no dopamine in the brain.
This means that they can suffer developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to painful episodes for affected children.
The condition is rare and often deadly, with many children with AADC deficiency not reaching adulthood.
The medicine, also known as eladocagene exuparvovec, consists of a virus that contains a working version of the AADC gene.
The treatment is delivered by millimetre precision to an exact location in the brain of the patient by a team of medics assisted by a robotic surgery tool.
When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme.
This is expected to enable the cells to produce the dopamine they need to work properly, which will improve symptoms of the condition.
It is the first NHS England commissioned gene therapy in the UK infused directly into the brain.
Gunreet was nine months old when she was diagnosed with AADC deficiency (Handout/PA)
Professor Manju Kurian, consultant paediatric neurologist at GOSH, said 'AADC deficiency is a rare condition but often a cruel one that has such a profound impact on children and their carers and families.
'We know children with the condition have painful episodes that can last for hours and, as their condition progresses, their life becomes more and more difficult.
'It's incredible to me that I can now prescribe novel gene therapies just as I would prescribe paracetamol and antibiotics.
'While the treatment is now available under the NHS at GOSH, we can only do this by working collaboratively across teams inside and outside the hospital, from physios and surgeons to dietitians and speech therapists, alongside partnerships with companies who supply these therapies.
'It's great to see how this treatment has been able to help babies and children across the country like Gunreet.
'The natural history of the condition is that most patients cannot fully hold their head or make any developmental progress after that milestone.
'Gunreet's progress over the last year has been really impressive in that context, as well as the virtual disappearance of the eye crises.
'We're hopeful that one day she will be able to talk or walk, as seen in some of the young patients treated in the clinical trial.'
Professor James Palmer, NHS medical director for specialised commissioning, said: 'This is wonderful news for Gunreet and her family, and a powerful example of how these commitments are translating into real improvements in people's lives.
'By bringing cutting-edge medicines like eladocagene exuparvovec into the health service and setting up our expert clinical teams to successfully deliver them, the NHS is making clear its commitment to improving care through innovation.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
12 hours ago
- The Guardian
Poorest parts of England to get £2.2bn more for NHS to cut care inequalities
England's poorest areas will get billions in extra health funding under new government plans to tackle stark inequalities in access to care and health outcomes. NHS services in deprived and coastal places will receive a £2.2bn boost this year to pay for more staff and equipment to help them close the wide gap in resources between them and well-off areas. Wes Streeting, the health secretary, will announce the move on Wednesday and hail it as a significant step towards ensuring that all patients get the same standard of care wherever they live. In a speech in Blackpool, he will decry that areas with the highest levels of illness and need for care often have low numbers of GPs, the longest waits for treatment and the poorest performing NHS services, a longstanding phenomenon known as 'the inverse care law'. He will portray the £2.2bn extra this year as a downpayment on a major redistribution of NHS funding, which is intended to improve the NHS in deprived areas. 'The truth is, those in greatest need often receive the worst quality healthcare. 'It flies in the face of the values the NHS was founded on. The circumstances of your birth shouldn't determine your worth,' he is expected to say. The £2.2bn is money that was due to be handed to England's 215 health trusts for 'deficit reduction' – to cover budget overspends – but has been freed up because Sir Jim Mackey, NHS England's chief executive, has told them to balance their books. Streeting has ordered a review of the Carr-Hill formula, which is used to decide the allocation of GP funding. The review, involving the advisory committee on resource allocation, will examine ways of ensuring that places with more illness get more money. The Nuffield Trust said the formula is 'inequitable', 'deeply flawed' and does not take account of levels of deprivation in areas covered by GP practices. The review will be the fourth such exercise since the formula came into use in 2004, without major changes resulting, it pointed out. Dr Becks Fisher, a GP and director of research and policy at the Nuffield Trust thinktank, also cautioned that while 'the government plans to pay for these changes by making savings in other parts of the NHS, there is no guarantee this will be successful.' Louise Gittins, the chair of the Local Government Association, said: 'Health inequalities are estimated to cost the NHS an extra £4.8bn a year, society around £31bn in lost productivity, and between £20bn and £32bn a year in lost tax revenue and benefit payments. Health is therefore a major determinant of economic performance and prosperity.' Prof Kate Pickett, an expert in health inequalities at York University and academic director of Health Equity North, said that recent years had brought 'worse health and more inequalities and a bigger north-south divide. 'We have repeatedly called for government to target spending to the places that are most in need. So Wes Streeting's drive to increase health spending in the most deprived places is very welcome.' But, she added, ministers should also cancel planned cuts to welfare benefits and start a public discussion about the merits of a basic income to improve population health in poor areas.
Rhyl Journal
12 hours ago
- Rhyl Journal
Mother's delight as gene therapy offers hope to three-year-old
Three-year-old Gunreet Kaur has a rare inherited condition that affects children's physical, mental and behavioural development. Children with aromatic l-amino acid decarboxylase (AADC) deficiency find it difficult to control their head, blood pressure and heart rate. But after receiving the new gene therapy, called Upstaza, Gunreet has made progress that her mother thought would never be possible, such as new movements and vocalising. It is hoped that she will make further strides as she ages. Gunreet, from Hayes in west London, was nine months old when she was diagnosed with the condition. She received the treatment in February 2024 at the world-renowned Great Ormond Street children's hospital (GOSH), which is the only hospital in the UK offering the treatment to children. Sandeep Kaur said Gunreet has made 'great progress' since her treatment. 'When Gunreet was about seven months old I noticed she wasn't reaching her milestones at the same age that her older brother did,' she said. 'She couldn't hold her own head up or reach out for items. She cried a lot and always wanted to be held. 'Since having the gene therapy, Gunreet has made great progress. 'She cries less, smiles more, and can reach for objects. 'She can hold her head up and is trying to sit up, she's recently learned how to roll from her stomach to her back which is fantastic to see. 'It means a lot to me that Gunreet was able to have this gene therapy – her general health has improved, she has more co-ordination, she can bring her palms together and is able to move her hand to her mouth.' AADC deficiency is caused by a mutation in the gene that produces the AADC enzyme, this enzyme is needed to produce a neurotransmitter called dopamine which is important in controlling movement. People with AADC deficiency do not have a working version of the enzyme, which means that they have little or no dopamine in the brain. This means that they can suffer developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to painful episodes for affected children. The condition is rare and often deadly, with many children with AADC deficiency not reaching adulthood. The medicine, also known as eladocagene exuparvovec, consists of a virus that contains a working version of the AADC gene. The treatment is delivered by millimetre precision to an exact location in the brain of the patient by a team of medics assisted by a robotic surgery tool. When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme. This is expected to enable the cells to produce the dopamine they need to work properly, which will improve symptoms of the condition. It is the first NHS England commissioned gene therapy in the UK infused directly into the brain. Professor Manju Kurian, consultant paediatric neurologist at GOSH, said 'AADC deficiency is a rare condition but often a cruel one that has such a profound impact on children and their carers and families. 'We know children with the condition have painful episodes that can last for hours and, as their condition progresses, their life becomes more and more difficult. 'It's incredible to me that I can now prescribe novel gene therapies just as I would prescribe paracetamol and antibiotics. 'While the treatment is now available under the NHS at GOSH, we can only do this by working collaboratively across teams inside and outside the hospital, from physios and surgeons to dietitians and speech therapists, alongside partnerships with companies who supply these therapies. 'It's great to see how this treatment has been able to help babies and children across the country like Gunreet. 'The natural history of the condition is that most patients cannot fully hold their head or make any developmental progress after that milestone. 'Gunreet's progress over the last year has been really impressive in that context, as well as the virtual disappearance of the eye crises. 'We're hopeful that one day she will be able to talk or walk, as seen in some of the young patients treated in the clinical trial.' Professor James Palmer, NHS medical director for specialised commissioning, said: 'This is wonderful news for Gunreet and her family, and a powerful example of how these commitments are translating into real improvements in people's lives. 'By bringing cutting-edge medicines like eladocagene exuparvovec into the health service and setting up our expert clinical teams to successfully deliver them, the NHS is making clear its commitment to improving care through innovation.'
Leader Live
17 hours ago
- Leader Live
Mother's delight as gene therapy offers hope to three-year-old
Three-year-old Gunreet Kaur has a rare inherited condition that affects children's physical, mental and behavioural development. Children with aromatic l-amino acid decarboxylase (AADC) deficiency find it difficult to control their head, blood pressure and heart rate. But after receiving the new gene therapy, called Upstaza, Gunreet has made progress that her mother thought would never be possible, such as new movements and vocalising. It is hoped that she will make further strides as she ages. Gunreet, from Hayes in west London, was nine months old when she was diagnosed with the condition. She received the treatment in February 2024 at the world-renowned Great Ormond Street children's hospital (GOSH), which is the only hospital in the UK offering the treatment to children. Sandeep Kaur said Gunreet has made 'great progress' since her treatment. 'When Gunreet was about seven months old I noticed she wasn't reaching her milestones at the same age that her older brother did,' she said. 'She couldn't hold her own head up or reach out for items. She cried a lot and always wanted to be held. 'Since having the gene therapy, Gunreet has made great progress. 'She cries less, smiles more, and can reach for objects. 'She can hold her head up and is trying to sit up, she's recently learned how to roll from her stomach to her back which is fantastic to see. 'It means a lot to me that Gunreet was able to have this gene therapy – her general health has improved, she has more co-ordination, she can bring her palms together and is able to move her hand to her mouth.' AADC deficiency is caused by a mutation in the gene that produces the AADC enzyme, this enzyme is needed to produce a neurotransmitter called dopamine which is important in controlling movement. People with AADC deficiency do not have a working version of the enzyme, which means that they have little or no dopamine in the brain. This means that they can suffer developmental delays, weak muscle tone and inability to control the movement of the limbs. It can also lead to painful episodes for affected children. The condition is rare and often deadly, with many children with AADC deficiency not reaching adulthood. The medicine, also known as eladocagene exuparvovec, consists of a virus that contains a working version of the AADC gene. The treatment is delivered by millimetre precision to an exact location in the brain of the patient by a team of medics assisted by a robotic surgery tool. When given to the patient, it is expected that the virus will carry the AADC gene into nerve cells, enabling them to produce the missing enzyme. This is expected to enable the cells to produce the dopamine they need to work properly, which will improve symptoms of the condition. It is the first NHS England commissioned gene therapy in the UK infused directly into the brain. Professor Manju Kurian, consultant paediatric neurologist at GOSH, said 'AADC deficiency is a rare condition but often a cruel one that has such a profound impact on children and their carers and families. 'We know children with the condition have painful episodes that can last for hours and, as their condition progresses, their life becomes more and more difficult. 'It's incredible to me that I can now prescribe novel gene therapies just as I would prescribe paracetamol and antibiotics. 'While the treatment is now available under the NHS at GOSH, we can only do this by working collaboratively across teams inside and outside the hospital, from physios and surgeons to dietitians and speech therapists, alongside partnerships with companies who supply these therapies. 'It's great to see how this treatment has been able to help babies and children across the country like Gunreet. 'The natural history of the condition is that most patients cannot fully hold their head or make any developmental progress after that milestone. 'Gunreet's progress over the last year has been really impressive in that context, as well as the virtual disappearance of the eye crises. 'We're hopeful that one day she will be able to talk or walk, as seen in some of the young patients treated in the clinical trial.' Professor James Palmer, NHS medical director for specialised commissioning, said: 'This is wonderful news for Gunreet and her family, and a powerful example of how these commitments are translating into real improvements in people's lives. 'By bringing cutting-edge medicines like eladocagene exuparvovec into the health service and setting up our expert clinical teams to successfully deliver them, the NHS is making clear its commitment to improving care through innovation.'
